Refractory Multiple Myeloma

Also known as: Refractory Multiple myeloma

DrugDrug NameDrug Description
DB08889CarfilzomibCarfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved on July 20, 2012.
DB00262CarmustineA cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
DB06317ElotuzumabElotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. Elotuzumab consists of the complementary determining regions (CDR) of the mouse antibody, MuLuc63, grafted onto human IgG1 heavy and kappa light chain frameworks. Elotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S. Food and Drug Administration. Elotuzumab is marketed under the brand Emplicitiā„¢ by Bristol-Myers Squibb.
DB06603PanobinostatPanobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market.
DB08910PomalidomidePomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
DrugDrug NamePhaseStatusCount
DB023422-Methoxyestradiol1Completed1
DB12707AR-421Active Not Recruiting1
DB00041Aldesleukin1Active Not Recruiting1
DB01169Arsenic trioxide1Completed1
DB00188Bortezomib1Completed4
DB00188Bortezomib1Recruiting1
DB00188Bortezomib1Terminated1
DB00188Bortezomib1Withdrawn1
DB11752Bryostatin 11Completed1
DB08889Carfilzomib1Active Not Recruiting1
DB00493Cefotaxime1Completed2
DB00531Cyclophosphamide1Completed2
DB00091Cyclosporine1Completed1
DB00091Cyclosporine1Terminated1
DB01234Dexamethasone1Active Not Recruiting1
DB01234Dexamethasone1Completed1
DB01234Dexamethasone1Recruiting1
DB00514Dextromethorphan1Active Not Recruiting1
DB00514Dextromethorphan1Completed1
DB00099Filgrastim1Completed1
DB01073Fludarabine1Completed2
DB01073Fludarabine1Recruiting1
DB01073Fludarabine1Terminated1
DB00619Imatinib1Completed1
DB06186Ipilimumab1Completed1
DB00480Lenalidomide1Completed2
DB00480Lenalidomide1Terminated1
DB11762Marizomib1Completed1
DB00688Mycophenolate mofetil1Completed1
DB00688Mycophenolate mofetil1Terminated1
DB00282Pamidronate1Completed1
DB06809Plerixafor1Completed1
DB08910Pomalidomide1Completed1
DB11836Sapanisertib1Completed1
DB00020Sargramostim1Active Not Recruiting1
DB11942Selinexor1Active Not Recruiting1
DB00877Sirolimus1Recruiting1
DB00398Sorafenib1Completed2
DB01268Sunitinib1Completed1
DB00864Tacrolimus1Recruiting1
DB06287Temsirolimus1Completed2
DB00541Vincristine1Completed1
DB02546Vorinostat1Completed1
DB05220Alisertib1 / 2Completed1
DB03496Alvocidib1 / 2Terminated1
DB09312Antilymphocyte immunoglobulin (horse)1 / 2Withdrawn1
DB00098Antithymocyte immunoglobulin (rabbit)1 / 2Withdrawn1
DB00928Azacitidine1 / 2Active Not Recruiting1
DB06769Bendamustine1 / 2Active Not Recruiting1
DB00188Bortezomib1 / 2Active Not Recruiting1
DB00188Bortezomib1 / 2Completed1
DB00188Bortezomib1 / 2Terminated3
DB00188Bortezomib1 / 2Withdrawn1
DB08875Cabozantinib1 / 2Not Yet Recruiting1
DB08889Carfilzomib1 / 2Not Yet Recruiting1
DB00493Cefotaxime1 / 2Active Not Recruiting1
DB00493Cefotaxime1 / 2Terminated1
DB00531Cyclophosphamide1 / 2Active Not Recruiting1
DB00531Cyclophosphamide1 / 2Terminated1
DB00091Cyclosporine1 / 2Active Not Recruiting3
DB00091Cyclosporine1 / 2Completed1
DB01234Dexamethasone1 / 2Active Not Recruiting3
DB01234Dexamethasone1 / 2Not Yet Recruiting1
DB01234Dexamethasone1 / 2Terminated1
DB00514Dextromethorphan1 / 2Active Not Recruiting3
DB00514Dextromethorphan1 / 2Terminated1
DB00997Doxorubicin1 / 2Terminated1
DB01590Everolimus1 / 2Active Not Recruiting1
DB00099Filgrastim1 / 2Active Not Recruiting1
DB01073Fludarabine1 / 2Active Not Recruiting2
DB01073Fludarabine1 / 2Completed1
DB00480Lenalidomide1 / 2Active Not Recruiting3
DB00480Lenalidomide1 / 2Completed1
DB01042Melphalan1 / 2Active Not Recruiting2
DB01042Melphalan1 / 2Completed1
DB01042Melphalan1 / 2Withdrawn1
DB00688Mycophenolate mofetil1 / 2Active Not Recruiting3
DB00688Mycophenolate mofetil1 / 2Completed1
DB12191Obatoclax1 / 2Terminated1
DB06603Panobinostat1 / 2Active Not Recruiting1
DB08910Pomalidomide1 / 2Active Not Recruiting1
DB00877Sirolimus1 / 2Withdrawn1
DB00864Tacrolimus1 / 2Withdrawn1
DB04960Tipifarnib1 / 2Terminated1
DB00041Aldesleukin2Completed1
DB00087Alemtuzumab2Active Not Recruiting2
DB03496Alvocidib2Completed1
DB09312Antilymphocyte immunoglobulin (horse)2Terminated1
DB00098Antithymocyte immunoglobulin (rabbit)2Terminated1
DB06769Bendamustine2Completed1
DB00112Bevacizumab2Unknown Status1
DB00188Bortezomib2Terminated2
DB01008Busulfan2Completed1
DB01008Busulfan2Recruiting1
DB01008Busulfan2Terminated1
DB08889Carfilzomib2Completed1
DB08889Carfilzomib2Terminated1
DB08889Carfilzomib2Withdrawn1
DB00493Cefotaxime2Completed2
DB00493Cefotaxime2Terminated1
DB00493Cefotaxime2Withdrawn1
DB01211Clarithromycin2Active Not Recruiting1
DB00531Cyclophosphamide2Completed2
DB00531Cyclophosphamide2Recruiting2
DB00531Cyclophosphamide2Terminated1
DB00531Cyclophosphamide2Withdrawn1
DB00091Cyclosporine2Active Not Recruiting2
DB00091Cyclosporine2Completed1
DB01234Dexamethasone2Active Not Recruiting1
DB01234Dexamethasone2Completed2
DB01234Dexamethasone2Terminated2
DB01234Dexamethasone2Unknown Status1
DB01234Dexamethasone2Withdrawn1
DB00514Dextromethorphan2Active Not Recruiting1
DB00514Dextromethorphan2Completed1
DB00514Dextromethorphan2Terminated2
DB00514Dextromethorphan2Unknown Status1
DB00514Dextromethorphan2Withdrawn1
DB12021Dinaciclib2Completed1
DB00997Doxorubicin2Terminated1
DB00773Etoposide2Completed1
DB00099Filgrastim2Completed2
DB01073Fludarabine2Active Not Recruiting4
DB01073Fludarabine2Completed1
DB01073Fludarabine2Recruiting2
DB01073Fludarabine2Terminated1
DB01073Fludarabine2Withdrawn1
DB00105Interferon Alfa-2b, Recombinant2Completed1
DB00480Lenalidomide2Completed1
DB00480Lenalidomide2Recruiting1
DB00480Lenalidomide2Unknown Status1
DB01042Melphalan2Active Not Recruiting1
DB01042Melphalan2Completed1
DB01042Melphalan2Withdrawn1
DB00563Methotrexate2Active Not Recruiting1
DB00563Methotrexate2Completed1
DB00959Methylprednisolone2Completed1
DB00688Mycophenolate mofetil2Active Not Recruiting4
DB00688Mycophenolate mofetil2Completed1
DB00688Mycophenolate mofetil2Recruiting2
DB00688Mycophenolate mofetil2Withdrawn1
DB01024Mycophenolic acid2Recruiting1
DB06809Plerixafor2Completed1
DB11870RG-47332Withdrawn1
DB05332Romiplostim2Terminated1
DB08877Ruxolitinib2Completed1
DB00877Sirolimus2Terminated1
DB09143Sonidegib2Recruiting1
DB00398Sorafenib2Completed1
DB01268Sunitinib2Completed1
DB00864Tacrolimus2Active Not Recruiting2
DB00864Tacrolimus2Completed1
DB00864Tacrolimus2Recruiting2
DB00864Tacrolimus2Terminated1
DB00864Tacrolimus2Withdrawn1
DB06287Temsirolimus2Completed1
DB01041Thalidomide2Active Not Recruiting1
DB04572Thiotepa2Recruiting1
DB06026Tivantinib2Completed1
DB12200Tivantinib2Completed1
DB01143Amifostine3Completed1
DB01234Dexamethasone3Active Not Recruiting1
DB00099Filgrastim3Terminated1
DB09570Ixazomib3Active Not Recruiting1
DB00480Lenalidomide3Active Not Recruiting1
DB01042Melphalan3Completed1
DB06809Plerixafor3Terminated1
DB00188Bortezomib4Completed1
DB01234Dexamethasone4Completed1
DB00514Dextromethorphan4Completed1
DB06603Panobinostat4Completed1
DB09312Antilymphocyte immunoglobulin (horse)Not AvailableActive Not Recruiting1
DB00098Antithymocyte immunoglobulin (rabbit)Not AvailableActive Not Recruiting1
DB00188BortezomibNot AvailableActive Not Recruiting1
DB00188BortezomibNot AvailableAvailable1
DB01008BusulfanNot AvailableActive Not Recruiting1
DB00958CarboplatinNot AvailableActive Not Recruiting1
DB00262CarmustineNot AvailableActive Not Recruiting1
DB00493CefotaximeNot AvailableActive Not Recruiting1
DB00531CyclophosphamideNot AvailableActive Not Recruiting1
DB00091CyclosporineNot AvailableActive Not Recruiting3
DB01609DeferasiroxNot AvailableCompleted1
DB01234DexamethasoneNot AvailableAvailable1
DB00773EtoposideNot AvailableActive Not Recruiting1
DB00099FilgrastimNot AvailableActive Not Recruiting1
DB00099FilgrastimNot AvailableTerminated1
DB01073FludarabineNot AvailableActive Not Recruiting3
DB00529FoscarnetNot AvailableCompleted1
DB01004GanciclovirNot AvailableCompleted1
DB00480LenalidomideNot AvailableAvailable1
DB01042MelphalanNot AvailableActive Not Recruiting2
DB00688Mycophenolate mofetilNot AvailableActive Not Recruiting3
DB00039PaliferminNot AvailableCompleted1
DB06809PlerixaforNot AvailableTerminated1
DB04572ThiotepaNot AvailableActive Not Recruiting1
DB12018UlocuplumabNot AvailableAvailable1
DB01610ValganciclovirNot AvailableCompleted1